Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction

Author： Axilrod Andrew C.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.12, 2007-12, pp. : 3189-3198

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction

By Seftel Allen D  

Therapy, Vol. 1, Iss. 2, 2004-11 ,pp. : 185-196

Future Medicine

Access to resources Recommend Favorite

Risk–benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 4, 2015-04 ,pp. : 436-443

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis

By  

Urologia Internationalis, Vol. 98, Iss. 2, 2016-08 ,pp. : 198-204

Karger

Access to resources Recommend Favorite

Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/prostatodynia?

By  

TRENDS IN UROLOGY AND MEN'S HEALTH, Vol. 6, Iss. 3, 2015-03 ,pp. : 40-41

John Wiley & Sons Inc

Access to resources Recommend Favorite

Couples' Satisfaction with Tadalafil Once Daily

By  

THE JOURNAL OF SEXUAL MEDICINE, Vol. 12, Iss. 3, 2015-03 ,pp. : 720-727

John Wiley & Sons Inc

Access to resources Recommend Favorite